Complete financial analysis of KORU Medical Systems, Inc. (KRMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of KORU Medical Systems, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Tullow Oil plc (TLW.L) Income Statement Analysis – Financial Results
- Vail Resorts, Inc. (0LK3.L) Income Statement Analysis – Financial Results
- National Silicon Industry Group Co., Ltd. (688126.SS) Income Statement Analysis – Financial Results
- Entra ASA (ENTOF) Income Statement Analysis – Financial Results
- 8i Acquisition 2 Corp. (LAX) Income Statement Analysis – Financial Results
KORU Medical Systems, Inc. (KRMD)
About KORU Medical Systems, Inc.
KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. It offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company also provides education and training materials to clinicians, patients, and patient advocates. It sells its products through direct sales and medical device distributors, as well as online. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28.52M | 27.90M | 23.49M | 24.18M | 23.16M | 17.35M | 15.98M | 12.29M | 12.25M | 11.24M | 8.70M | 7.76M | 6.39M | 4.92M | 3.77M | 3.44M | 2.35M | 1.73M | 1.75M | 1.56M | 1.53M | 1.66M | 1.76M | 2.09M | 2.07M |
| Cost of Revenue | 11.81M | 12.53M | 9.72M | 9.24M | 8.31M | 6.54M | 6.52M | 4.72M | 4.64M | 4.56M | 3.39M | 2.82M | 2.25M | 1.66M | 1.26M | 1.24M | 899.98K | 663.51K | 728.52K | 726.46K | 723.56K | 959.54K | 1.33M | 1.11M | 1.13M |
| Gross Profit | 16.71M | 15.37M | 13.77M | 14.94M | 14.85M | 10.81M | 9.46M | 7.57M | 7.60M | 6.69M | 5.31M | 4.94M | 4.14M | 3.26M | 2.51M | 2.20M | 1.45M | 1.07M | 1.02M | 833.76K | 804.83K | 697.02K | 427.94K | 978.94K | 939.85K |
| Gross Profit Ratio | 58.59% | 55.09% | 58.62% | 61.78% | 64.13% | 62.29% | 59.20% | 61.57% | 62.08% | 59.47% | 61.04% | 63.69% | 64.77% | 66.32% | 66.53% | 63.85% | 61.67% | 61.75% | 58.27% | 53.44% | 52.66% | 42.08% | 24.33% | 46.93% | 45.50% |
| Research & Development | 5.74M | 4.96M | 2.47M | 1.30M | 740.48K | 241.12K | 60.70K | 237.49K | 207.28K | 468.15K | 218.15K | 147.58K | 90.33K | 35.52K | 27.92K | 22.44K | 59.93K | 42.03K | 41.82K | 44.03K | 42.19K | 40.27K | 40.84K | 35.34K | 80.94K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.37M | 20.61M | 17.86M | 12.03M | 9.77M | 8.20M | 7.91M | 7.77M | 5.94M | 4.79M | 3.85M | 3.54M | 2.66M | 1.97M | 1.70M | 1.31M | 1.13M | 993.42K | 984.63K | 1.07M | 876.39K | 827.87K | 635.53K | 827.99K | 1.01M |
| Other Expenses | 870.39K | 0.00 | 679.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -9.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 26.98M | 26.15M | 20.80M | 13.74M | 10.85M | 8.75M | 7.97M | 8.31M | 6.42M | 5.54M | 4.30M | 3.88M | 2.85M | 2.07M | 1.79M | 1.42M | 1.25M | 1.09M | 1.11M | 1.19M | 1.05M | 949.57K | 802.20K | 1.08M | 1.18M |
| Cost & Expenses | 38.79M | 38.68M | 30.52M | 22.98M | 19.16M | 15.29M | 14.49M | 13.03M | 11.07M | 10.10M | 7.69M | 6.70M | 5.10M | 3.73M | 3.05M | 2.66M | 2.15M | 1.76M | 1.83M | 1.92M | 1.77M | 1.91M | 2.13M | 2.19M | 2.30M |
| Interest Income | 561.33K | 145.59K | 13.08K | 42.40K | 80.66K | 28.10K | 0.00 | 2.94K | 0.00 | 5.62K | 7.43K | 8.08K | 12.85K | 8.72K | 1.35K | 8.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.89K | 3.41K | 512.00 | 4.55K | 28.28K | 31.54K | 36.39K | 47.50K | 51.68K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 870.39K | 587.14K | 463.13K | 418.60K | 340.23K | 309.26K | 308.71K | 300.61K | 271.57K | 283.88K | 232.96K | 190.97K | 103.98K | 65.77K | 64.80K | 79.36K | 68.20K | 60.43K | 79.09K | 81.82K | 80.55K | 81.44K | 84.84K | 84.97K | 87.80K |
| EBITDA | -9.40M | -10.19M | -6.57M | 1.61M | 4.34M | 2.37M | 1.88M | -474.20K | 1.42M | 1.36M | 1.24M | 1.25M | 1.42M | 1.30M | 774.76K | 855.89K | 261.71K | 38.29K | -9.16K | -277.54K | -165.09K | -171.12K | -289.42K | -17.38K | -149.54K |
| EBITDA Ratio | -32.96% | -36.40% | -27.84% | 16.71% | 33.36% | 18.94% | 11.22% | -3.52% | 11.79% | 12.78% | 14.35% | 16.25% | 22.00% | 26.37% | 20.87% | 24.96% | 11.15% | 12.28% | 4.55% | -17.79% | -7.44% | -10.33% | -14.12% | 5.54% | -26.45% |
| Operating Income | -10.27M | -10.78M | -7.03M | -1.25M | 585.68K | 1.16M | 1.48M | -736.25K | 1.18M | 1.15M | 1.01M | 1.06M | 1.29M | 1.19M | 721.52K | 779.01K | 193.51K | -22.14K | -88.25K | -359.35K | -245.64K | -252.56K | -374.26K | -102.35K | -237.34K |
| Operating Income Ratio | -36.01% | -38.65% | -29.93% | -5.19% | 2.53% | 6.71% | 9.29% | -5.99% | 9.65% | 10.20% | 11.58% | 13.68% | 20.17% | 24.28% | 19.11% | 22.65% | 8.24% | -1.28% | -5.06% | -23.03% | -16.07% | -15.25% | -21.28% | -4.91% | -11.49% |
| Total Other Income/Expenses | 496.40K | 105.71K | 665.09K | 60.52K | 110.74K | 12.41K | 85.18K | -40.45K | -38.81K | -72.86K | 2.78K | -24.29K | -7.97K | -1.71K | -59.06K | -54.16K | -193.51K | -232.59K | -129.56K | -40.14K | -31.53K | -14.84K | -11.24K | -2.11K | 237.34K |
| Income Before Tax | -9.77M | -10.68M | -6.36M | -1.19M | 696.42K | 1.18M | 1.57M | -776.70K | 1.14M | 1.07M | 1.01M | 1.04M | 1.28M | 1.19M | 662.46K | 724.86K | 0.00 | -254.72K | -217.82K | -399.49K | -277.17K | -267.39K | -385.50K | -104.46K | 159.46K |
| Income Before Tax Ratio | -34.27% | -38.27% | -27.09% | -4.94% | 3.01% | 6.78% | 9.82% | -6.32% | 9.33% | 9.56% | 11.62% | 13.37% | 20.05% | 24.25% | 17.55% | 21.08% | 0.00% | -14.68% | -12.48% | -25.60% | -18.13% | -16.14% | -21.92% | -5.01% | 7.72% |
| Income Tax Expense | 3.97M | -2.01M | -1.80M | 17.80K | 132.07K | 266.38K | 483.08K | -241.70K | 359.71K | 321.42K | 307.02K | 312.35K | 465.29K | 489.03K | -226.98K | -306.00K | 196.01K | 232.59K | 129.56K | 1.40K | 831.00 | 800.00 | 572.00 | 2.11K | -487.64K |
| Net Income | -13.74M | -8.66M | -4.56M | -1.21M | 564.35K | 910.57K | 1.09M | -535.00K | 782.86K | 753.12K | 703.43K | 725.76K | 815.89K | 704.09K | 889.44K | 1.03M | -2.50K | -254.72K | -217.82K | -400.89K | -278.00K | -268.19K | -386.08K | -104.46K | 250.30K |
| Net Income Ratio | -48.18% | -31.05% | -19.42% | -5.01% | 2.44% | 5.25% | 6.80% | -4.35% | 6.39% | 6.70% | 8.09% | 9.35% | 12.77% | 14.31% | 23.56% | 29.97% | -0.11% | -14.68% | -12.48% | -25.69% | -18.19% | -16.19% | -21.95% | -5.01% | 12.12% |
| EPS | -0.30 | -0.19 | -0.10 | -0.03 | 0.01 | 0.02 | 0.03 | -0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.00 | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 | -0.02 | 0.00 | 0.01 |
| EPS Diluted | -0.30 | -0.19 | -0.10 | -0.03 | 0.01 | 0.02 | 0.03 | -0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.00 | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 | -0.02 | 0.00 | 0.01 |
| Weighted Avg Shares Out | 45.60M | 45.00M | 44.39M | 41.93M | 38.78M | 38.13M | 37.87M | 37.83M | 37.99M | 37.63M | 36.66M | 36.01M | 34.25M | 36.24M | 35.38M | 34.83M | 32.68M | 29.87M | 26.47M | 22.70M | 23.54M | 23.50M | 23.50M | 23.35M | 20.63M |
| Weighted Avg Shares Out (Dil) | 45.60M | 45.00M | 44.39M | 41.93M | 39.06M | 38.92M | 38.39M | 37.88M | 37.99M | 37.63M | 36.66M | 36.04M | 35.10M | 36.85M | 35.38M | 34.83M | 32.68M | 29.87M | 26.47M | 22.70M | 23.54M | 23.50M | 23.50M | 23.35M | 23.12M |
KORU Medical Systems, Inc. (KRMD) Q4 2023 Earnings Call Transcript
KORU Medical Systems, Inc. (KRMD) Q4 2023 Earnings Call Transcript
KORU Medical Systems, Inc. Announces 2023 Fourth Quarter, Full Year Financial Results, and 2024 Guidance
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the fourth...
KORU Medical (KRMD) Forms New Deal on Subcutaneous Infusion
One key aspect of the collaboration of KORU Medical (KRMD) with a pharmaceutical manufacturer is the exploration of new therapeutic settings.
KORU Medical Systems Announces a Feasibility Study to Enter Ambulatory Infusion Settings with a Commercialized Biologic
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a collaboration with a global...
KORU Medical Systems Signs a Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for a Novel Subcutaneous Immunoglobulin
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased to announce a clinical supply...
KORU Medical Systems to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients, today announced...
KORU Medical Systems to Participate in Piper Sandler's 35th Annual Healthcare Conference
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients, today...
KORU Medical Systems, Inc. (KRMD) Q3 2023 Earnings Call Transcript
KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Linda Tharby - Chief Executive Officer and President, Director Tom Adams - Chief Medical Officer Conference Call Participants Caitlin Cronin -...
KORU Medical Systems, Inc. Appoints Ken Miller as Chief Commercial Officer
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients,...
KORU Medical Systems, Inc. Announces 2023 Third Quarter Financial Results and Updates Full Year 2023 Outlook
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today...
Source: https://incomestatements.info
Category: Stock Reports